NCT06740942 Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke
| NCT ID | NCT06740942 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Acute Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-08-04 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-08-04 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to * to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients; * to evaluate the influence of lesion location on autonomic dysfunction; * to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and * to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia. Researchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions. Participants will * undergo cardiovascular autonomic function testing; * receive structural and functional MR imaging; * provide blood samples for determinaton of serological biomarkers auf dysautonomia.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of either * acute ischemic stroke with either an ischemic lesion visible on CT/MRI or persistent focal deficits 24 hours after symptom onset, or * Transient ischemic attack with transient clinical deficits including motor or speech disturbance and not restricted to isolated vertigo/dizziness, visual disturbance, or sensory disturbance. * symptom onset within 72h prior to hospital admission, * a pre-stroke/TIA ability to walk without help from another person (modified Rankin scale score \< 4), * age \> 18 years, and * informed consent by either the patient or a legal representative (including a spouse) Exclusion Criteria: * In-hospital stroke, * contraindications to MR imaging (e.g., claustrophobia, pregnancy, pacemakers, implants), * known moderate to severe dementia, * previous structural brain damage (except leukoariosis due to cerebral small vessel disease), * hemodynamically relevant stenosis of the common or internal carotid artery, or * left heart failure with estimated left ventricular ejection fraction \< 50%, * concomitant systemic illness that can lead to dysautonomia, such as an active infection, thyroid disease, or neurodegenerative disorder (e.g. PD, MSA).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06740942 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06740942 currently recruiting?
Yes, NCT06740942 is actively recruiting participants. Contact the research team at e.schlemm@uke.de for enrollment information.
Where is the NCT06740942 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT06740942 clinical trial?
NCT06740942 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.